## Duccio Medini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/498205/publications.pdf

Version: 2024-02-01

46 papers

7,141 citations

279798 23 h-index 265206 42 g-index

49 all docs

49 docs citations

49 times ranked

7755 citing authors

#	Article	IF	CITATIONS
1	High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007–2011: Concordant predictions between MATS and genetic MATS. Human Vaccines and Immunotherapeutics, 2021, 17, 3230-3238.	3.3	7
2	Literature Mining and Mechanistic Graphical Modelling to Improve mRNA Vaccine Platforms. Frontiers in Immunology, 2021, 12, 738388.	4.8	4
3	Computational modeling of microfluidic data provides high-throughput affinity estimates for monoclonal antibodies. Computational and Structural Biotechnology Journal, 2021, 19, 3664-3672.	4.1	3
4	Systematic characterization of human response to H1N1 influenza vaccination through the construction and integration of personalized transcriptome response profiles. Scientific Reports, 2021, 11, 20821.	3.3	0
5	A quantitative systems pharmacology approach to support mRNA vaccine development and optimization. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1448-1451.	2.5	8
6	OUP accepted manuscript. American Journal of Epidemiology, 2021, , .	3.4	1
7	Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines. Frontiers in Immunology, 2021, 12, 757151.	4.8	3
8	A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model. BMC Infectious Diseases, 2021, 21, 1244.	2.9	2
9	Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland. MSphere, 2020, 5, .	2.9	5
10	The Pangenome: A Data-Driven Discovery in Biology. , 2020, , 3-20.		11
11	Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine. Clinical Immunology, 2019, 209, 108275.	3.2	18
12	Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine, 2019, 37, 991-1000.	3.8	64
13	Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery. Frontiers in Immunology, 2019, 10, 113.	4.8	107
14	STRAIN: an R package for multi-locus sequence typing from whole genome sequencing data. BMC Bioinformatics, 2019, 20, 347.	2.6	0
15	Interplay Between Virulence and Variability Factors as a Potential Driver of Invasive Meningococcal Disease. Computational and Structural Biotechnology Journal, 2018, 16, 61-69.	4.1	14
16	Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B <i>Neisseria meningitidis</i> lsolated from 2009 to 2013 in the Republic of Ireland. MSphere, 2018, 3, .	2.9	18
17	Potential impact of the 4CMenB vaccine on oropharyngeal carriage of Neisseria meningitidis. Journal of Infection, 2017, 75, 511-520.	3.3	4
18	Exploring the Limitations of Peripheral Blood Transcriptional Biomarkers in Predicting Influenza Vaccine Responsiveness. Complexity, 2017, 2017, 1-9.	1.6	2

#	Article	IF	Citations
19	Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States. MSphere, 2017, 2, .	2.9	37
20	In-silico prediction and deep-DNA sequencing validation indicate phase variation in $115$ Neisseria meningitidis genes. BMC Genomics, $2016,17,843.$	2.8	22
21	Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. Vaccine, 2016, 34, 2579-2584.	3.8	22
22	Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines. BMC Medicine, 2016, 14, 98.	5.5	10
23	Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans. PLoS ONE, 2016, 11, e0157066.	2.5	43
24	MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine, 2015, 33, 2629-2636.	3.8	95
25	Ten years of pan-genome analyses. Current Opinion in Microbiology, 2015, 23, 148-154.	5.1	498
26	Bexsero® chronicle. Pathogens and Global Health, 2014, 108, 305-316.	2.3	89
27	Horizontal Gene Transfer and the Role of Restriction-Modification Systems in Bacterial Population Dynamics., 2014,, 169-190.		1
28	Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine, 2013, 32, 124-130.	3.8	81
29	Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine, 2013, 31, 4968-4974.	3.8	123
30	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases, The, 2013, 13, 416-425.	9.1	261
31	Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines. Vaccine Journal, 2012, 19, 1609-1617.	3.1	59
32	The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine, 2012, 30, B67-B72.	3.8	25
33	<i>Neisseria meningitidis</i> is structured in clades associated with restriction modification systems that modulate homologous recombination. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4494-4499.	7.1	198
34	Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19490-19495.	7.1	267
35	Comparative genomics of the genus Bifidobacterium. Microbiology (United Kingdom), 2010, 156, 3243-3254.	1.8	116
36	Pangenomic Reverse Vaccinology. , 2010, , 203-221.		1

#	Article	IF	CITATIONS
37	Building an insurance against modern pandemics. Current Opinion in Investigational Drugs, 2010, 11, 126-30.	2.3	1
38	Adjuvanted H5N1 vaccine induces early CD4 <sup>+</sup> T cell response that predicts long-term persistence of protective antibody levels. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3877-3882.	7.1	242
39	Microbiology in the post-genomic era. Nature Reviews Microbiology, 2008, 6, 419-430.	28.6	324
40	Comparative genomics: the bacterial pan-genome. Current Opinion in Microbiology, 2008, 11, 472-477.	5.1	868
41	Towards a universal group BStreptococcusvaccine using multistrain genome analysis. Expert Review of Vaccines, 2006, 5, 687-694.	4.4	27
42	Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Current Opinion in Microbiology, 2006, 9, 532-536.	5.1	76
43	Protein Homology Network Families Reveal Step-Wise Diversification of Type III and Type IV Secretion Systems. PLoS Computational Biology, 2006, 2, e173.	3.2	51
44	Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: Implications for the microbial "pan-genome". Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13950-13955.	7.1	2,161
45	The microbial pan-genome. Current Opinion in Genetics and Development, 2005, 15, 589-594.	3.3	1,151
46	Atomic scale fractal dimensionality in proteins. Journal of Chemical Physics, 2003, 118, 2405-2410.	3.0	1